Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115.
Microbiol Spectr. 2019 Mar;7(2). doi: 10.1128/microbiolspec.GPP3-0001-2017.
The surface of the Gram-positive opportunistic pathogen Streptococcus agalactiae, or group B Streptococcus (GBS), harbors several carbohydrate and protein antigens with the potential to be effective vaccines. Capsular polysaccharides of all clinically-relevant GBS serotypes coupled to immunogenic proteins of both GBS and non-GBS origin have undergone extensive testing in animals that led to advanced clinical trials in healthy adult women. In addition, GBS proteins either alone or in combination have been tested in animals; a fusion protein construct has recently advanced to human clinical studies. Given our current understanding of the antigenicity and immunogenicity of the wide array of GBS surface antigens, formulations now exist for the generation of viable vaccines against diseases caused by GBS.
革兰氏阳性机会性病原体无乳链球菌(或 B 组链球菌,GBS)的表面存在多种具有成为有效疫苗潜力的碳水化合物和蛋白质抗原。所有具有临床相关性的 GBS 血清型的荚膜多糖与 GBS 和非 GBS 来源的免疫原性蛋白偶联,已经在动物中进行了广泛的测试,这些测试推动了健康成年女性的先进临床试验。此外,GBS 蛋白单独或组合已在动物中进行了测试;一种融合蛋白构建体最近已进入人体临床试验。鉴于我们目前对 GBS 广泛表面抗原的抗原性和免疫原性的了解,现在已经存在针对 GBS 引起的疾病的活疫苗的生成方案。